Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

130 ARTÍCULOS , VIENDO DEL 31 AL 45

Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease

Portelius E, Zetterberg H, Dean RA, Marcil A, Bourgeois P, Nutu M, Andreasson U, Siemers E, Mawuenyega KG, Sigurdson WC, May PC, Paul SM, Holtzman DM, Blennow K, Bateman RJ.

J Alzheimers Dis. 2012;31(2):335-41. doi: 10.3233/JAD-2012-120508.

Peptidylarginine deiminase modulates the physiological roles of enolase via citrullination: links between altered multifunction of enolase and neurodegenerative diseases

Jang B, Jeon YC, Choi JK, Park M, Kim JI, Ishigami A, Maruyama N, Carp RI, Kim YS, Choi EK.

Biochem J. 2012 Jul 15;445(2):183-92. doi: 10.1042/BJ20120025.

[For a new definition of the Alzheimer's disease]

Dubois B.

Rev Neurol (Paris). 2012 Jun;168(6-7):467-8. doi: 10.1016/j.neurol.2012.03.001. Epub 2012 May 2.

Exercise is more effective than diet control in preventing high fat diet-induced β-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice

Maesako M, Uemura K, Kubota M, Kuzuya A, Sasaki K, Hayashida N, Asada-Utsugi M, Watanabe K, Uemura M, Kihara T, Takahashi R, Shimohama S, Kinoshita A.

J Biol Chem. 2012 Jun 29;287(27):23024-33. doi: 10.1074/jbc.M112.367011. Epub 2012 May 4.

Blood markers of oxidative stress in Alzheimer's disease

Skoumalová A, Hort J.

J Cell Mol Med. 2012 Oct;16(10):2291-300. doi: 10.1111/j.1582-4934.2012.01585.x.

Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria

Renard D, Castelnovo G, Wacongne A, Le Floch A, Thouvenot E, Mas J, Gabelle A, Labauge P, Lehmann S.

J Neurol. 2012 Nov;259(11):2429-33. doi: 10.1007/s00415-012-6520-8. Epub 2012 May 11.

[The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia]

Croisile B, Auriacombe S, Etcharry-Bouyx F, Vercelletto M; National Institute on Aging (u.s.); Alzheimer Association.

Rev Neurol (Paris). 2012 Jun;168(6-7):471-82. doi: 10.1016/j.neurol.2011.11.007. Epub 2012 May 12.

[Synaptic vesicle recycling and Alzheimer's disease]

Xia ZM, Hu YE.

Sheng Li Ke Xue Jin Zhan. 2012 Feb;43(1):5-10.

Alzheimer's disease: biological aspects, therapeutic perspectives and diagnostic tools

Di Carlo M, Giacomazza D, San Biagio PL.

J Phys Condens Matter. 2012 Jun 20;24(24):244102. doi: 10.1088/0953-8984/24/24/244102. Epub 2012 May 18.

[Searching for biomarkers to diagnose dementia]

Yanagisawa K.

Nihon Rinsho. 2012 May;70(5):785-9.

Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease

Spies PE, Verbeek MM, van Groen T, Claassen JA.

Front Biosci (Landmark Ed). 2012 Jun 1;17(6):2024-34. doi: 10.2741/4035.

Biomarkers of neurodegeneration - not only Alzheimer's disease and not only cerebrospinal fluid: a guest-editor's introduction

Lewczuk P.

J Neural Transm (Vienna). 2012 Jul;119(7):735-7. doi: 10.1007/s00702-012-0836-5.

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, Maguire RP, Blennow K, Lundmark J, Staufenbiel M, Orgogozo JM, Graf A.

Lancet Neurol. 2012 Jul;11(7):597-604. doi: 10.1016/S1474-4422(12)70140-0. Epub 2012 Jun 6.

Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults

Paternicò D, Galluzzi S, Drago V, Bocchio-Chiavetto L, Zanardini R, Pedrini L, Baronio M, Amicucci G, Frisoni GB.

Alzheimers Dement. 2012 Nov;8(6):520-7. doi: 10.1016/j.jalz.2011.10.003. Epub 2012 Jun 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias